NEXTGEN BIOLOGICS, INC – Trademark Portfolio

Entity Type: 03

NEXTGEN BIOLOGICS, INC holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 14 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 2 Nice Classification classes. Currently, 1 trademark is registered and 4 are pending. Notable registered marks include NEOMATRIX. The owner is based in GAINESVILLE, FL.

218 NW 2ND AVENUE

GAINESVILLE, FL 32601

15 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

NEXTGEN BIOLOGICS, INC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (14 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

40
Treatment & Processing (5 filings)

Treatment of materials

Frequently Asked Questions

How many trademarks does NEXTGEN BIOLOGICS, INC have?

NEXTGEN BIOLOGICS, INC has 15 U.S. trademarks filed with the USPTO. Of these, 1 registered, 4 pending, 9 abandoned, 1 cancelled.

What trademark classes does NEXTGEN BIOLOGICS, INC file in?

NEXTGEN BIOLOGICS, INC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are NEXTGEN BIOLOGICS, INC's most well-known trademarks?

NEXTGEN BIOLOGICS, INC's registered trademark portfolio includes well-known marks such as NEOMATRIX. These are among 1 currently registered trademark in the portfolio.

What is NEXTGEN BIOLOGICS, INC's trademark registration success rate?

NEXTGEN BIOLOGICS, INC has a 9% trademark registration rate, with 1 out of 11 resolved applications resulting in successful registration. Currently, 4 applications are pending review.